Analysts expect Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) to announce ($0.03) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Osmotica Pharmaceuticals’ earnings. Osmotica Pharmaceuticals posted earnings per share of ($4.99) during the same quarter last year, which indicates a positive year over year growth rate of 99.4%. The company is scheduled to report its next earnings report on Thursday, November 14th.
According to Zacks, analysts expect that Osmotica Pharmaceuticals will report full year earnings of ($0.25) per share for the current financial year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.12) per share, with EPS estimates ranging from ($0.17) to ($0.06). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Osmotica Pharmaceuticals.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.06. The firm had revenue of $57.53 million during the quarter, compared to the consensus estimate of $57.90 million.
NASDAQ OSMT traded down $0.05 on Wednesday, hitting $3.02. The stock had a trading volume of 286 shares, compared to its average volume of 111,856. Osmotica Pharmaceuticals has a 52-week low of $2.20 and a 52-week high of $9.90. The company has a quick ratio of 1.41, a current ratio of 1.70 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $157.14 million and a P/E ratio of -6.24. The business has a 50-day moving average of $3.49.
Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp raised its position in shares of Osmotica Pharmaceuticals by 5.6% during the 2nd quarter. Northern Trust Corp now owns 99,449 shares of the company’s stock valued at $378,000 after buying an additional 5,230 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Osmotica Pharmaceuticals during the 1st quarter valued at $45,000. Deutsche Bank AG purchased a new stake in shares of Osmotica Pharmaceuticals during the 4th quarter valued at $111,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Osmotica Pharmaceuticals during the 2nd quarter valued at $142,000. Finally, Acadian Asset Management LLC raised its position in shares of Osmotica Pharmaceuticals by 277.5% during the 2nd quarter. Acadian Asset Management LLC now owns 53,846 shares of the company’s stock valued at $206,000 after buying an additional 39,584 shares in the last quarter. Hedge funds and other institutional investors own 11.66% of the company’s stock.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.